SG11202100178YA - Treatment of neuropathy with igf-1-encoding dna constructs and hgf-encoding dna constructs - Google Patents
Treatment of neuropathy with igf-1-encoding dna constructs and hgf-encoding dna constructsInfo
- Publication number
- SG11202100178YA SG11202100178YA SG11202100178YA SG11202100178YA SG11202100178YA SG 11202100178Y A SG11202100178Y A SG 11202100178YA SG 11202100178Y A SG11202100178Y A SG 11202100178YA SG 11202100178Y A SG11202100178Y A SG 11202100178YA SG 11202100178Y A SG11202100178Y A SG 11202100178YA
- Authority
- SG
- Singapore
- Prior art keywords
- dna constructs
- encoding dna
- hgf
- igf
- neuropathy
- Prior art date
Links
- 201000001119 neuropathy Diseases 0.000 title 1
- 230000007823 neuropathy Effects 0.000 title 1
- 208000033808 peripheral neuropathy Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862699667P | 2018-07-17 | 2018-07-17 | |
| PCT/IB2019/001399 WO2020079489A2 (en) | 2018-07-17 | 2019-07-16 | Treatment of neuropathy with igf-1-encoding dna constructs and hgf-encoding dna constructs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202100178YA true SG11202100178YA (en) | 2021-02-25 |
Family
ID=69162823
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202100178YA SG11202100178YA (en) | 2018-07-17 | 2019-07-16 | Treatment of neuropathy with igf-1-encoding dna constructs and hgf-encoding dna constructs |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20200024323A1 (en) |
| EP (1) | EP3823982A4 (en) |
| JP (1) | JP7380670B2 (en) |
| KR (1) | KR20210025122A (en) |
| CN (1) | CN112469732A (en) |
| AU (1) | AU2019362458A1 (en) |
| CA (1) | CA3106085A1 (en) |
| SG (1) | SG11202100178YA (en) |
| WO (1) | WO2020079489A2 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7074300B2 (en) * | 2017-10-18 | 2022-05-24 | ヘリックスミス カンパニー， リミテッド | Treatment of neurological disorders with DNA constructs that reduce interference from gabapentinoids and express HGF variants |
| US11554179B2 (en) * | 2018-07-19 | 2023-01-17 | Helixmith Co., Ltd | Lyophilized pharmaceutical compositions for naked DNA gene therapy |
| WO2023158214A1 (en) * | 2022-02-15 | 2023-08-24 | 주식회사 헬릭스미스 | Composition for preventing or treating sarcopenia by using insulin-like growth factor-1 isoform |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2135306A1 (en) * | 1992-05-08 | 1993-11-25 | Bradford A. Jameson | Igf-1 analogs |
| DE69731660T2 (en) * | 1996-12-02 | 2005-12-22 | Valentis Inc., Burlingame | INSULINARY GROWTH FACTOR I (IGF-I) EXPRESSION SYSTEM AND METHOD OF USE |
| GB9926968D0 (en) * | 1999-11-15 | 2000-01-12 | Univ London | Treatment of neurological disorders |
| US8546143B2 (en) | 2001-01-09 | 2013-10-01 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a target gene |
| EP1868637A1 (en) * | 2005-03-18 | 2007-12-26 | UCL Business PLC | Mechano growth factor peptides and their use |
| WO2012109567A2 (en) * | 2011-02-11 | 2012-08-16 | The Rockefeller University | Treatment of angiogenesis disorders |
| US9963493B2 (en) | 2011-11-03 | 2018-05-08 | Viromed Co., Ltd. | Gene therapy for diabetic neuropathy using an HGF isoform |
| US10639351B2 (en) * | 2013-10-22 | 2020-05-05 | Helixmith Co., Ltd. | Method for treating amyotrophic lateral sclerosis with a polynucleotide encoding two or more isoforms of hepatocyte growth factor |
| WO2016039163A1 (en) | 2014-09-10 | 2016-03-17 | クリングルファーマ株式会社 | Hgf preparation suitable for treatment of nervous diseases |
| KR20190060016A (en) | 2014-10-20 | 2019-05-31 | 뉴럴스템, 인크. | Stable neural stem cells comprising an exogenous polynucleotide coding for a growth factor and methods of use thereof |
| KR102245539B1 (en) * | 2018-02-12 | 2021-04-29 | 주식회사 지앤피바이오사이언스 | Composition for increasing expression level of growth factor genes containing core-shell structured microparticles as effective component |
-
2019
- 2019-07-16 WO PCT/IB2019/001399 patent/WO2020079489A2/en unknown
- 2019-07-16 JP JP2021502742A patent/JP7380670B2/en active Active
- 2019-07-16 EP EP19872729.9A patent/EP3823982A4/en not_active Withdrawn
- 2019-07-16 US US16/513,560 patent/US20200024323A1/en not_active Abandoned
- 2019-07-16 SG SG11202100178YA patent/SG11202100178YA/en unknown
- 2019-07-16 CN CN201980047529.XA patent/CN112469732A/en active Pending
- 2019-07-16 CA CA3106085A patent/CA3106085A1/en active Pending
- 2019-07-16 KR KR1020217004788A patent/KR20210025122A/en unknown
- 2019-07-16 AU AU2019362458A patent/AU2019362458A1/en active Pending
-
2022
- 2022-11-11 US US18/054,606 patent/US20240002462A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020079489A2 (en) | 2020-04-23 |
| US20200024323A1 (en) | 2020-01-23 |
| EP3823982A4 (en) | 2022-04-13 |
| AU2019362458A1 (en) | 2021-03-11 |
| JP7380670B2 (en) | 2023-11-15 |
| CA3106085A1 (en) | 2020-04-23 |
| EP3823982A2 (en) | 2021-05-26 |
| JP2022500353A (en) | 2022-01-04 |
| CN112469732A (en) | 2021-03-09 |
| KR20210025122A (en) | 2021-03-08 |
| WO2020079489A3 (en) | 2020-07-16 |
| US20240002462A1 (en) | 2024-01-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL282233A (en) | Nucleic acid constructs and methods of use | |
| ZA202006905B (en) | Gene therapy constructs and methods of use | |
| IL252917A0 (en) | Nucleic acid constructs and gene therapy vectors for use in the treatment of wilson disease | |
| SG10202009182RA (en) | Dna antibody constructs and method of using same | |
| HK1251969A1 (en) | Anti-her2 antibodies and methods of use | |
| EP3583406C0 (en) | Integrated plasmo-photonic biosensor and method of use | |
| HK1247100A1 (en) | Dna antibody constructs and method of using same | |
| EP3635114A4 (en) | Creation and use of guide nucleic acids | |
| EP3704269C0 (en) | Oligonucleotide constructs and uses thereof | |
| IL279272A (en) | Nucleic acid constructs and methods of using same | |
| IL265359A (en) | Modified oligonucleotides and methods of use | |
| IL275070A (en) | Fcrn antibodies and methods of use thereof | |
| SG11202100178YA (en) | Treatment of neuropathy with igf-1-encoding dna constructs and hgf-encoding dna constructs | |
| IL273841A (en) | Antibodies targeting cd137 and methods of use thereof | |
| IL290279A (en) | Implantable constructs and uses thereof | |
| IL290233A (en) | Antigen-binding protein constructs and uses thereof | |
| ES2982270T3 (en) | Gene therapy constructs and procedures for the treatment of hearing loss | |
| IL277269A (en) | Formulations and methods for treating photosynthetic organisms and enhancing qualities and quantities of yields with glycan composite formulations | |
| IL265236A (en) | Therapeutic multi-targeting constructs and uses thereof | |
| HK1246194A1 (en) | Calicheamicin constructs and methods of use | |
| IL288685A (en) | Antigen-binding protein constructs and uses thereof | |
| SG11202100139VA (en) | Treatment of neuropathy with dna constructs expressing igf-1 isoforms | |
| GB201709763D0 (en) | Biological materials and methods | |
| IL271303A (en) | Charge-tagged nucleotides and methods of use thereof | |
| EP3585819A4 (en) | Antibody constructs and methods of treating cancer |